Devita, Hellman, and Rosenberg's Cancer

LWBK1006-08 LWW-Govindan-Review December 12, 2011 18:49

98 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 8.18. In most cases, normal bone marrow and gastrointestinal (GI) precursor

cells are able to counteract the effects of cytotoxic chemotherapy because:

A. They are not exposed to the chemotherapeutic agent.

B. They have intact mechanisms for apoptosis and cell-cycle arrest.

C. They have rapid turnover.

D. They possess resistance mechanisms.

Question 8.19. All of the following are true concerning p53, EXCEPT:

A. It is a tumor suppressor gene.

B. It is a potent inducer of apoptosis.

C. It causes S phase arrest in the cell cycle.

D. It can be protective against chemotherapy cytotoxicity.

Question 8.20. Drug resistance in advanced tumors is thought to be due to:

A. Mutations in important genes in cell-cycle regulation

B. Drug-specific spontaneous mutations

C. Wild-type p53

D. Low tumor growth rate

Question 8.21. The final stage of the programmed cell death pathway is mediated by:

A. Bcl-2

B. p53

C. Tumor necrosis factor

D. Caspase cascade

Question 8.22. Imatinib inhibits all of the following, EXCEPT:

A. EGFR

B. C-kit

C. Platelet-derived growth factor

D. Bcr-abl

Question 8.23. Cetuximab use in colorectal cancer is characterized by:

A. Approval in the first-line setting

B. Limited utility as monotherapy

C. High toxicity

D. Response rates of 21% to 23% when used with irinotecan

Question 8.24. All of the following are characteristics of a randomized discontinuation

trial design, EXCEPT:

A. Phase 2 study design

B. Preferred for drugs with preexisting predictive biomarker

C. Patients with stable disease are randomized to continue or discontinue

therapy

D. Primary end point could be time to progression after randomization